EUVIMEDEUVIMED entdecken
Crossref

Mechanistic insights into Schisandrin C as the active anti-renal fibrosis ingredient of Schisandra chinensis: a network pharmacology analysis and transcriptomics integrated experimental verification

Xinping Yang, Xijier Qiaolongbatu, Rui Shen, Yuting Wang, Wenjing Li, Li Wang, Chunyan Zhou, Taishan Wei, Zhenghua Wu

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04349-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Xinping Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of P…. Hauptthemen laut MEDLINE: Schisandra, Lignans, Polycyclic Compounds, Kidney. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Shanghai Scientific and Technological Committee, Bethune Quest - Pharmaceutical research capacity Building Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schisandra chinensis (Turcz.) Baill (Sch) is a Traditional Chinese Medicinal (TCM) plant. It is divided into southern and northern. Sch is widely used in treating chronic kidney disease (CKD), which is primarily characterized by renal interstitial fibrosis. However, the knowledge of components in Sch that play a major role in treating renal fibrosis (RF) and its mechanism of action in vivo remains unclear. Here, the active ingredients of Sch for treating RF were initially identified through network pharmacological analysis and molecular docking technology. Cytological assays were conducted in vitro, and a gentamicin-induced zebrafish model was established to assess the anti-RF activity in vivo. Finally, the efficacy and mechanisms of these active components were further validated through transcriptomic analysis at the cellular level. Sch C has a stable combination (-8.69 kcal/mol) with Transforming Growth Factor Beta Receptor I (TGFBR1), which was identified as the main active ingredient of Sch in the treatment of RF. Transcriptomic and cell experiments revealed that Sch C inhibited the excessive accumulation of extracellular matrix (ECM) by regulating the TGF-β signaling pathway and PI3K-Akt signaling pathway, in which fibrosis markers CDH2 and α-SMA were significantly downregulated, and collagen expressions of COL3A1 and COL1A1 were reduced. In the zebrafish model, Sch C exhibited significant anti-fibrotic activity, suggesting its potential as a key anti-RF compound in Sch. This study significantly advances our understanding of the anti-fibrotic activity of Sch and elucidates its anti-RF mechanism. The findings provide a solid foundation for further research and development of effective anti-RF drugs derived from Sch.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchisandraLignansPolycyclic CompoundsKidneyKidney DiseasesAntifibrotic AgentsAnimalsZebrafishFibrosisNetwork PharmacologyCyclooctanesTranscriptomeHumansMolecular Docking SimulationSignal TransductionDisease Models, Animal

Stichwörter der Autor:innen

Network pharmacology analysisRenal fibrosisSchisandrin CTranscriptomicsZebrafish

Substanzen

LignansPolycyclic CompoundsCyclooctanesschizandrinAntifibrotic Agents

Autor:innen und Institutionen

  • Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 20024…
  • Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
  • Xinjiang Uygur Autonomous Region Center for Drug Evaluation and Inspection, Urumqi, 830002, Xinjiang, China.
  • School of Pharmacy, Kunming Medical University, Kunming, 650500, China.
  • Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China. wuzhenghua@sjtu.edu.cn.

Förderung

  • Shanghai Scientific and Technological Committee
  • Bethune Quest - Pharmaceutical research capacity Building Program

Zitieren

APA

Yang, X., Qiaolongbatu, X., Shen, R., Wang, Y., Li, W., Wang, L., Zhou, C., Wei, T., & Wu, Z. (2025). Mechanistic insights into Schisandrin C as the active anti-renal fibrosis ingredient of Schisandra chinensis: a network pharmacology analysis and transcriptomics integrated experimental verification. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04349-8

Vancouver

Yang X, Qiaolongbatu X, Shen R, Wang Y, Li W, Wang L, et al. Mechanistic insights into Schisandrin C as the active anti-renal fibrosis ingredient of Schisandra chinensis: a network pharmacology analysis and transcriptomics integrated experimental verification. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04349-8

BibTeX
@article{Yang2025,
  author = {Yang, Xinping and Qiaolongbatu, Xijier and Shen, Rui and Wang, Yuting and Li, Wenjing and Wang, Li and Zhou, Chunyan and Wei, Taishan and Wu, Zhenghua},
  title = {Mechanistic insights into Schisandrin C as the active anti-renal fibrosis ingredient of Schisandra chinensis: a network pharmacology analysis and transcriptomics integrated experimental verification},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04349-8}
}
Kostenlos starten →